Researchers at Barrow Neurological Institute discovered a link between wildfire smoke and neurodegenerative diseases like Parkinson's and Alzheimer's. Wildfire smoke particles activate astrocytes, leading to inflammation and damage to nearby brain cells.
A nationwide study found that people living within 500 feet of dry cleaners had a 14% greater risk of developing Parkinson's disease compared to those living further away. The study, led by Barrow Neurological Institute, highlights the potential role of environmental exposures in disease development.
The Barrow Neurological Institute is conducting a Phase 1/2 clinical trial investigating ibogaine as a therapeutic agent for treating traumatic brain injury (TBI). Researchers aim to enroll 40 participants and determine how effectively ibogaine addresses TBI symptoms and quality of life.
The Barrow Neuro Analytics Center has nearly doubled its dedicated research space to 18,000 square feet, supporting growing neurological research programs. Researchers at the center are globally renowned for their work on Parkinson's disease, Alzheimer's, and other neurological disorders using data-focused methods.
A new study by Barrow Neurological Institute and the University of Calgary recommends greater occipital nerve blocks and elevating intravenous prochlorperazine to offer effective and safe treatment for migraine attacks. The guidelines aim to reduce opioid reliance and improve patient outcomes in Emergency Departments.
A Barrow Neurological Institute study found a positive association between ambient trichloroethylene (TCE) and Parkinson's disease risk. The researchers identified a potential link between TCE exposure and an increased risk of Parkinson's disease, particularly in individuals living near facilities emitting the chemical.
A US study published in Alzheimer's & Dementia found that 37% of dementia cases could be linked to cardiometabolic diseases, with the strongest connection in the South. Hypertension was the leading cause, accounting for 9.6% of cases.
The ALL ALS Consortium has recruited over 300 participants across two studies, ASSESS and PREVENT, aiming to disrupt traditional ALS research by making data and samples available worldwide. The consortium seeks to discover new drug targets and approaches for effective treatments.
Researchers will test the hypothesis that environmental manganese exposure is associated with the progression of Parkinson's symptoms and measure neuroinflammation in the brain using MRI scans. The study aims to inform environmental regulations for manganese worldwide and address an environmental justice concern.
Researchers at Barrow Neurological Institute collected and displayed Vesalius' anatomical manikins for the first time, showcasing their enduring influence on modern anatomic teaching. The display highlights the significance of these works in revolutionizing anatomical education and training.
The Access for All in ALS Consortium has successfully enrolled its first participant, marking a significant step forward for ALS research. The consortium aims to disrupt the clinical research landscape using open science methods to advance ALS research.
Researchers created an interactive atlas that deconstructs traumatic brain injury (TBI) at the molecular level, identifying cell-specific targets for therapies. The atlas may improve treatment outcomes by allowing doctors to use precision-medicine tools to tailor treatments to individual patients.
A new study published in PLOS One found that ALS patients treated by neurologists received interventions endorsed by the American Academy of Neurology, including non-invasive ventilation and feeding tubes. Disparities were found in treatment among Black and disadvantaged patients, highlighting the need for equitable care.
A recent study found that people living in areas with high levels of fine particulate matter have a 56% greater risk of developing Parkinson's disease. The Mississippi-Ohio River Valley and parts of Texas, Kansas, and eastern Michigan were identified as regions with higher rates of the disease.
A new national ALS research consortium, Access for All in ALS, has been launched with a $16.7 million NIH award. The consortium will include 34 clinical sites nationwide and generate a longitudinal biorepository linked to detailed clinical information.